Clinical trials completed
Print Edition
PHASE 1 clinical trials on a homegrown neutralizing antibody treatment for the novel coronavirus have been completed in Shanghai.
The new drug, JS016, was given to 40 healthy volunteers. The trials are the first of its kind to test neutralizing antibody treatment against the coronavirus in healthy people.
The trials showed the drug was safe and tolerable for human use.
JS016 is co-developed by Shanghai Junshi Biosciences and the Institute of Microbiology under the Chinese Academy of Sciences.
Clinical trials began at the Huashan Hospital on June 7, and led by Dr Zhang Jing and Dr Zhang Wenhong, who is also the leader of the expert team for coronavirus treatment in Shanghai.
The 40 volunteers were given the drug by July 7. To date, no side effects related to the doses have not been found.
Junshi said the company plans to start clinical trials on affected people as soon as possible.
Previous tests on monkeys showed JS016 can block the virus from entering cells, and decrease the virus in the lungs of affected monkeys.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
